UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.68 -0.38 (-0.47%) GOLD FUTURES
2,430.00 +12.60 (+0.52%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,579.48 +2,500.89 (+4.80%)
VKTX Nov 2024 110.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:57PM EDT. Market open.
| Previous close | 8.0000 |
| Open | 4.5000 |
| Bid | 6.3000 |
| Ask | 7.5000 |
| Strike | 110.00 |
| Expiry date | 2024-11-15 |
| Day's range | 4.5000 - 4.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
- Zacks
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
© 2024 Yahoo. All rights reserved.